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Abstract Preserving upper extremity (UE) function in
patients with Duchenne muscular dystrophy (DMD) is
extremely important as it is related to independence and
quality of life. For clinical decision making, knowledge of
variables associated with UE function is necessary. This
knowledge is, however, limited. Therefore, this study aims
to gain more insight into the variables associated with UE
function in DMD. Data from an international web-based
questionnaire on UE function, obtained from 213 DMD
patients, were used. Six dependent variables regarding UE
function were used in multivariable linear regression
analyses. In addition, 26 independent variables regarding
patient characteristics, medication, therapy, supportive
aids, pain, stiffness and participation were used. Twelve
independent variables showed a significant relation to UE
function. Variables with a negative relation to UE function
were: later disease stage, occurrence of scoliosis, higher
age, use of UE splints, more frequent stiffness complaints,
more limitations due to stiffness, more frequent elbow
pain, and having physical therapy. A positive relation with
UE function was seen for going to school or work, use of
corticosteroids, higher BMI, and higher age at diagnosis.
These variables explained 56–81 % of the variation of the
different measures of UE function. Knowledge of variables
associated with UE function is very important in the
clinical management of DMD patients. The results of this
study suggest that corticosteroid use and participation in
school and work related activities are positively related to
UE function in DMD patients, as well as reducing pain and
stiffness and preventing scoliosis.
Keywords Duchenne muscular dystrophy  Upper limb 
Associated variables  Regression analysis
Introduction
Duchenne muscular dystrophy (DMD) is one of the most
common neuromuscular disorders. DMD is an X-linked
recessive disorder affecting about 1:5000 live born males
[24]. The disease is characterized by progressive muscle
weakening leading to functional disabilities. In an early
stage boys with DMD have difficulties with walking, run-
ning and climbing stairs. Around the age of 12 they
become wheelchair confined and from that age on, upper
extremity (UE) function also starts to deteriorate [14, 23].
The loss of UE function leads to severe problems in the
performance of daily activities and participation in society
[14], ultimately affecting independence and quality of life
[25].
Until now no cure has been found for DMD, however,
life expectancy has rapidly increased over the last few
decades. Currently, life expectancy is about 30–40 years
[8, 18, 19], which means that DMD patients are in a
wheelchair for the largest part of their lives and that they
are fully dependent on the use of their arms during this life
span. As limitations in UE function have a huge impact on
the lives of DMD patients, preservation of UE function is
very important. To this end, effective interventions are
necessary and variables associated with UE function should
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be taken into consideration when making clinical decisions.
Our knowledge of effective interventions and variables
associated with UE function is, however, limited.
Several studies have indicated that treatment with cor-
ticosteroids has beneficial effects on the preservation of UE
function in DMD patients [1, 6, 12]. In addition, Wagner
et al. recommended daily stretching exercises, particularly
of the distal upper extremities, in these patients [32].
However, scientific evidence for the effects of UE
stretching exercises in DMD is lacking. Furthermore, evi-
dence for the effects of physical therapy and occupational
therapy on the preservation of UE function is limited. Yet,
there is preliminary evidence for the efficacy of stretching
and the use of splints for the lower extremities [4, 28].
To our knowledge there are no observational studies that
have investigated variables associated with UE function in
DMD, such as ‘participant characteristics’, ‘pain’, ‘stiff-
ness’ and ‘participation’. However, this information could
play an important role in clinical decision making with
regard to the preservation (or perhaps even improvement)
of UE function. Therefore, this study aimed to gain more
insight into the variables associated with UE function in
DMD using multivariable linear regression analysis of data
obtained through a large international web-based survey
[14].
Methods
Participant characteristics
This study was part of a larger study in which 344 par-
ticipants from 14 different countries responded to a web-
based questionnaire [14]. We excluded respondents that did
not agree with the clinical Duchenne phenotype, based on
the diagnostic criteria of Emery et al. [9]. Participants were
also excluded if the diagnosis was made after the age of
10 years, or when participants who did not use corticos-
teroids and who were 14 years or older, were not wheel-
chair confined [9]. In total 213 participants were included
in this study. Participants were on average 13 years (range
1–35 years) and 55 % of the participants were wheelchair
confined (median age 10 years). Corticosteroid use was
reported by 55 % of the respondents, while 11 % had
stopped using corticosteroids and 34 % had never used
steroids. In addition, 49 % of the participants had a mild or
severe scoliosis. A detailed description of the participants’
characteristics has been reported in a previous study [14].
This study was approved by the medical-ethical committee
in the Arnhem-Nijmegen region (The Netherlands) and
performed in accordance with the ethical standards laid
down in the 1964 Declaration of Helsinki and its later
amendments.
The web-based questionnaire
The web-based questionnaire consisted of 224 items in
total. Some items were extracted from existing question-
naires such as the capabilities of upper extremity ques-
tionnaire (CUE) [21], the ABILHAND questionnaire [31]
(including few additional questions), and questions con-
cerning pain and stiffness that were modified from the
University of Michigan Upper Extremity Questionnaire
[27]. Besides these existing questionnaires, questions
regarding ‘patient characteristics, ‘medication’, ‘therapy’,
‘supportive aids’ and ‘participation’ were added to the
web-based questionnaire.
For this study we used a subset of items from the total
questionnaire (Table 1). To find the underlying dimensions
and reduce the number of items for regression analysis,
exploratory factor analysis was performed on the subcate-
gories ‘pain’, ‘stiffness’, and ‘upper extremity function’
[15]. Dependent variables were the Brooke scale and the
factor sum scores of the CUE and ABILHAND. Factor
analysis of the CUE resulted in three factors: ‘basic hand
function’, ‘heavy lifting’ and ‘light or no lifting’. ‘Basic
hand function’ contains items regarding grasping and
manipulating objects with the fingers. ‘Heavy lifting’
contains items regarding lifting and moving heavy objects
and lifting one’s own body weight, whereas ‘light or no
lifting’ contains items that require arm movements with no
or minimal additional weight, such as reaching for objects
or sliding light objects over a tabletop. Factor analysis of
the ABILHAND resulted in two factors: ‘gross hand
function’ and ‘fine hand function’. ‘Gross hand function’
contains items such as ‘washing and drying one’s hands’,
‘turning on and off a tap’, and ‘opening a lunchbox’,
whereas the factor ‘fine hand function’ contains items such
as ‘buttoning up a shirt’, ‘cutting nails’ and ‘inserting a key
in a keyhole’. For the independent variables, factor analysis
was performed on the pain and stiffness questions. Factor
analysis performed on the pain questions resulted in six
factors: ‘pain limitations’, ‘pain severity (not shoulder)’,
‘distal pain frequency’, ‘shoulder pain’, ‘proximal pain
frequency (not shoulder)’ and ‘elbow pain frequency’.
Factor analysis performed on the stiffness questions
resulted in three factors: ‘stiffness frequency’, ‘stiffness
limitations’ and ‘stiffness severity’. All descriptions were
chosen based on the communalities of the items within one
factor. Ultimately, we used the sum scores of the items
within each factor for further analysis [15]. In total 32
variables were included in this study.
Data analysis
Median values and ranges were used to describe the con-
tinuous variables. Valid percentages were used to describe
J Neurol (2016) 263:1810–1818 1811
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Table 1 Overview of variables
Category Variable Description
Outcome measures (dependent variables)
Upper
extremity
function
Brooke Brooke scale [2]
Basic hand
function
Sum scores of the items regarding basic hand function from the capabilities of upper extremity
questionnaire (CUE) [21]a
Heavy lifting Sum scores of the items regarding heavy lifting from the CUEa
Light or no lifting Sum scores of the items regarding light or no lifting from the CUEa
Gross hand
function
Sum scores of the items regarding gross hand function from the Abilhand questionnaire [31]a
Fine hand
function
Sum scores of the items regarding fine hand function from the Abilhand questionnairea
Possible variables associated with UE function (independent variables)
Patient
characteristics
Age Age when participant responded to questionnaire
Disease stage Stage of the disease according the criteria of Bushby et al. [3]
BMI Body Mass Index
Age at diagnosis Age when the diagnosis Duchenne was established
Injuries Occurrence of severe injuries (e.g., bone fracture) in the arms
Scoliosis Occurrence of spinal deformities (e.g., scoliosis)
Medication Corticosteroids Use of corticosteroids
Homeopathic
remedies
Use of homeopathic remedies
Therapy Physical therapy Participants that receive physical therapy
Practice at home Participants that practice at home
Hydro therapy Participants that receive hydro therapy
Occupational
therapy
Participants that receive occupational therapy
Supportive aids Splints Use of arm/hand splints
Arm supports Use of arm supports
Participation School/work Participants that go to school or work
Sport Participants that participate in sports
Hobby Participants that practice a hobby
Pain Pain limitations Sum scores of the items regarding functional limitations due to pain in the arms and/or handsa
Pain severity (not
shoulder)
Sum scores of the items regarding pain severity in the arms and/or hands (except for the shoulder
segment)a
Distal pain
frequency
Sum scores of the items regarding pain frequency in the wrist, fingers and thumba
Shoulder pain Sum scores of the items regarding shoulder pain frequency and severitya
Proximal pain
frequency (not
shoulder)
Sum scores of the items regarding pain frequency in the lower arm and upper arma
Elbow pain
frequency
Sum scores of the items regarding pain frequency in the elbowa
Stiffness Stiffness
frequency
Sum scores of the items regarding stiffness frequency in the arms and/or handsa
Stiffness
limitations
Sum scores of the items regarding functional limitations due to stiffness in the arms and/or handsa
Stiffness severity Sum scores of the items regarding stiffness severity in the arms and/or handsa
a The sum scores resulted from an exploratory factor analysis that was performed on the capabilities of upper extremity questionnaire [21], the
Abilhand questionnaire [31] and pain and stiffness questionnaires adapted from the University of Michigan Upper Extremity Questionnaire [27].
The complete overview of the exploratory factor analysis is described in a different study [15]
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categorical variables. Univariable regression analysis and
stepwise multivariable linear regression analysis were
performed to identify variables associated with the mea-
sures of UE function (dependent variables). Independent
variables consisted of items from the sub categories ‘pa-
tient characteristics’, ‘medication’, ‘therapy’, ‘supportive
aids’, ‘participation’, ‘pain’ and ‘stiffness’ (Table 1). Data
were analyzed using IBM SPSS Statistics version 20 for
Windows (IBM, Somers, NY, USA).
Results
Participant characteristics
In total, 213 participants were included in this study, of
which 198 participants filled in the complete questionnaire
and 15 participants filled in only a part of the questionnaire,
as they ended the questionnaire prematurely. Table 2
describes the outcome measures that relate to UE function.
Table 3 describes the possible associated variables in the
subcategories: ‘patient characteristics’, ‘medication’,
‘therapy’, ‘supportive aids’, ‘participation’, ‘pain’ and
‘stiffness’.
Univariable regression analysis
The results of univariable linear regression analyses of
potential variables associated with UE function in patients
with DMD are presented in Table 4. For each dependent
variable the independent variables that were associated
with a p value\0.2 were entered in the multivariable linear
regression analysis.
Multivariable regression analysis
Multivariable stepwise linear regression analysis revealed a
total of 12 different variables associated with one or more
aspects of UE function (Table 5). These associated vari-
ables explained 56–81 % of the variation of the different
measures of UE function. The variables that were posi-
tively related to UE function were: ‘going to school or
work’, ‘use of corticosteroids’, ‘higher BMI’ and ‘later age
at diagnosis’. The variables that were negatively related to
UE function were: ‘later disease stage’, ‘occurrence of
scoliosis’, ‘higher age’, ‘use of UE splints, ‘more frequent
stiffness complaints’, ‘more limitations due to stiffness’,
‘more frequent elbow pain’ and ‘having physical therapy’.
Discussion
The aim of our study was to gain insight into the variables
associated with UE function in boys and men with DMD.
Knowledge of these variables is essential for the clinical
management of these patients. In this study we found four
variables that were positively associated with UE function
and eight variables that had a negative association with UE
function.
The finding that use of corticosteroids was positively
related to UE function is not surprising, as it has been
proven that this medication can retard disease progression
[1, 6, 12, 26]. The positive relation between going to school
or work and UE function may be attributed to the fact that
people that go to school or work are often physically more
active than people that do not. Indeed, physical activity is
important to maintain functional independence [13, 22].
The finding that patients who were diagnosed at a later age
have better UE function may be due to the fact these
patients usually have a slower disease progression. Another
positive determinant of UE function was a higher BMI,
which seems to be counterintuitive because, on the one
hand, it is associated with arms that weigh more, requiring
more strength to lift the arms. On the other hand, a higher
BMI is often related to a better nutritional status (even
though protein loss may still occur when BMI is high
Table 2 Descriptives of
outcome measures
Outcome measure (min–max possible score) N Median (min–max) Category N (valid %)
Brooke 213 Brooke 1 7 (33.8)
Brooke 2 43 (20.2)
Brooke 3 17 (8.0)
Brooke 4 14 (6.6)
Brooke 5 40 (18.8)
Brooke 6 27 (12.7)
Basic hand function (8–56) 210 48 (8–56)
Heavy lifting (10–70) 210 31 (10–70)
Light or no lifting (12–84) 210 57 (12–84)
Gross hand function (15–45) 189 42 (16–48)
Fine hand function (11–33) 191 19 (10–30)
J Neurol (2016) 263:1810–1818 1813
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Table 3 Descriptives of
possible associated variables
Predictors (min–max possible score) N Median
(min–max)
Category N (valid %)
Age 213 13.1 (1.5–35.2)
Disease stage 213 Early ambulatory 66 (31.0)
Late ambulatory 29 (13.6)
Early non ambulatory 24 (11.3)
Late non ambulatory 94 (44.1)
BMI 209 20.1 (5.9–44.1)
Age at diagnosis 213 4 (0–10)
Injuries 213 No 186 (87.3)
Yes 27 (12.7)
Scoliosis 213 No scoliosis 109 (51.2)
Mild scoliosis 66 (31.0)
Severe scoliosis 38 (17.8)
Corticosteroids 212 No 72 (34.0)
Not anymore 24 (11.3)
Yes 116 (54.7)
Homeopathic remedies 213 No 99 (46.5)
Yes 114 (53.5)
Physical therapy 213 No 17 (8.0)
Not anymore 19 (8.9)
With periods of no
therapy
31 (14.6)
Yes continuously 146 (68.5)
Practice at home 213 No 123 (57.7)
On average once a week 38 (17.8)
On average once a day 40 (18.8)
More than once a day 12 (5.6)
No 92 (43.2)Hydro therapy 213
Yes 121 (56.8)
Occupational therapy 213 No 123 (57.7)
Not anymore 37 (17.4)
With periods of no
therapy
31 (14.6)
Yes continuously 22 (10.3)
Splints 213 No 192 (90.6)
Yes 20 (9.4)
Arm supports 213 No 195 (91.5)
Yes 18 (8.5)
School/work 200 No 34 (17.0)
Yes 166 (83.0)
Sport 198 No 122 (61.6)
Yes 76 (38.4)
Hobby 198 No 34 (17.2)
Yes 164 (82.8)
Pain limitations (0–140) 213 0 (0–140)
Pain severity (not shoulder) (0–120) 213 0 (0–120)
Distal pain frequency (0–36) 213 0 (0–24)
Shoulder pain (0–32) 213 0 (0–21)
Proximal pain frequency (not shoulder)
(0–24)
213 0 (0–22)
1814 J Neurol (2016) 263:1810–1818
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[16, 17]) and malnutrition occurs more often in people with
a low BMI, as it is associated with dysphagia, typically
occurring in the later stages of DMD [7, 30]. Malnutrition
can be related to a lack of energy, increased fatigability,
reduced muscle strength, and muscle wasting leading to
loss of functional capacity [7, 20]. Thus, a higher BMI may
be associated with a reduced likelihood of malnutrition,
which could explain the positive relationship with UE
function independent of disease stage. Nevertheless, future
studies should try to disentangle these interrelationships to
optimize clinical management.
With regard to the variables that have a negative rela-
tionship with UE function, a later disease stage and a
higher age are well conceivable based on the progressive
nature of DMD. Although we found no studies that related
the occurrence of scoliosis to UE function, it can be
expected that deformity of the spine has a negative effect
on sitting balance and reduced sitting balance has a nega-
tive influence on UE function [5, 10, 11]. The negative
relation of UE function with pain and stiffness is not sur-
prising as pain and stiffness complaints are known to have
a negative impact on general physical functioning [29].
However, based on our analysis, stiffness seems to have a
stronger relation with UE function than pain, as only one
pain variable (elbow pain frequency) was related to one
dependent variable (Brooke scale), whereas stiffness vari-
ables were related to all measures of UE function. One
possible explanation for the fact that stiffness seems to
have a stronger relation with UE function is that DMD
patients experience more stiffness-related than pain-related
UE problems [14]. The fact that only elbow pain frequency
relates to UE function could be because the elbow is often
used as a hinge point on the arm rest or table to perform
daily activities. Pain in the elbow could, therefore, be the
key element in the restriction of the performance of UE
activities. Remarkably, stiffness severity was not identified
as a variable associated with UE function, which may
indicate that stiffness severity is harder to score subjec-
tively than stiffness frequency and stiffness limitations.
Another explanation might be that the three stiffness
variables were rather strongly correlated (r[ 0.6), as a
result of which stiffness severity did not add to the
explained variance of UE function in the multivariable
model. The finding that use of splints and physical therapy
showed a negative association with UE function is proba-
bly caused by the likelihood that these interventions are
recommended more often to relatively severely affected
patients [4, 28]. In contrast, no relationship was found
between UE function and occupational therapy,
hydrotherapy or practicing at home. We hypothesize that
the absence of this relation might lie in the relatively short
duration of these interventions, as they are only applied for
a few hours per week or even less. Therefore, exposure to
therapy might not be high enough for the therapy to be
effective. Going to school or work, in contrast, stimulates
the use of the arm and hand over a much longer time span,
which could explain its positive relation with UE function.
A limitation of this study is that our results are based on
a questionnaire that was primarily designed to gain insight
in UE function in patients with DMD, not for the identi-
fication of variables associated with UE function. Thus, the
possible variables associated with UE function in DMD
were limited to those addressed in this questionnaire,
leaving the possibility that there might be other variables
associated with UE function that were not investigated.
Another limitation is that the cross-sectional design of our
study does not allow any inferences with regard to the
nature of the observed relationships (cause vs. conse-
quence). Third, our results are entirely subjective in nature,
as no objective tests of UE function, pain or stiffness were
performed. Therefore, the results of this study should be
interpreted with caution. Nevertheless, our study addressed
26 possible variables associated with UE function in more
than 200 patients with DMD, which provides a good basis
for further (longitudinal) prognostic studies, using both
subjective and more objective outcome measures, to
improve our understanding of the most essential variables
associated with function in DMD.
It is important to realize that several of the variables
associated with UE function in DMD that were identified in
this study can be influenced by proper clinical manage-
ment. For example, use of corticosteroids and living an
active life by participating in school and work related
activities can be stimulated by clinicians. In addition,
prevention of scoliosis, maintaining a stable sitting bal-
ance, and reduction of pain and stiffness complaints may
be attainable by regular attention from physical and
occupational therapists, including the prescription of
Table 3 continued
Predictors (min–max possible score) N Median
(min–max)
Category N (valid %)
Elbow pain frequency (0–12) 213 0 (0–11)
Stiffness frequency (0–84) 212 2 (0–84)
Stiffness limitations (0–140) 212 0 (0–140)
Stiffness severity (0–140) 212 2 (0–140)
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optimal assistive devices. Future longitudinal research
should investigate whether proper clinical management of
patients with DMD can indeed slow down the progression
of UE impairments, UE activity limitations, and related
participation restrictions.
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